• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Glob Health Med . Poor prognosis of patients with severe COVID-19 admitted to an infectious disease intensive care unit during the pandemic caused

tetano

Editor, Senior Moderator
Glob Health Med


. 2022 Apr 30;4(2):122-128.
doi: 10.35772/ghm.2021.01121.
Poor prognosis of patients with severe COVID-19 admitted to an infectious disease intensive care unit during the pandemic caused by the Delta variant in Japan


Keigo Sekihara[SUP] 1 [/SUP], Takatoshi Shibasaki[SUP] 1 2 [/SUP], Tatsuya Okamoto[SUP] 1 [/SUP], Chihiro Matsumoto[SUP] 1 [/SUP], Kuniaki Ito[SUP] 1 [/SUP], Kana Fujimoto[SUP] 1 [/SUP], Fumito Kato[SUP] 1 2 [/SUP], Wataru Matsuda[SUP] 2 [/SUP], Kentaro Kobayashi[SUP] 2 [/SUP], Ryo Sasaki[SUP] 2 [/SUP], Tatsuki Uemura[SUP] 1 2 [/SUP], Akio Kimura[SUP] 1 2 [/SUP], Haruhito Sugiyama[SUP] 3 [/SUP], Norihiro Kokudo[SUP] 4 [/SUP]



Affiliations

Abstract

During the surge of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) delta variant, our institution operated an intensive care unit (ICU) for patients with severe COVID-19. The study aim was to determine the survival rate and treatment outcomes of patients with severe COVID-19 treated in the ICU during the surge. A total of 23 consecutive patients with severe COVID-19 were admitted to the ICU between August 5 and October 6, 2021. Patients received multidrug therapy consisting of remdesivir, tocilizumab, heparin, and methylprednisolone. The patients were divided into two groups based on the ordinal scale (OS): a non-invasive oxygen therapy (OS-6) group, and an invasive oxygen therapy (OS-7) group. There were 13 (57%) and 10 (43%) patients in the OS-7 and OS-6 groups, respectively. All patients were unvaccinated. Sixteen patients (70%) were male. The median age was 53 years; the median body mass index (BMI) was 30.3 kg/m2; and the median P/F ratio on admission was 96. The 30-day survival rate was 69% and was significantly poorer in the OS-7 group (54%) than in the OS-6 group (89%; p = 0.05). The prevalence of obesity (p = 0.05) and the Sequential Organ Failure Assessment (SOFA) score on admission (p < 0.01) were significantly higher in the OS-7 group. Seven patients in the OS-7 group (54%) developed bacteremia. A low P/F ratio on admission was a significant unfavorable prognostic factor (hazard ratio: 10.9; p = 0.03). The survival rate was poor, especially in patients requiring invasive oxygen therapy. More measures are needed to improve the treatment outcomes of patients with severe COVID 19.

Keywords: SARS-CoV-2 infection; mechanical ventilation; mortality; secondary hospital-acquired infection.
 
Back
Top Bottom